Usefulness and Potential Pitfalls of Sialic Acid Determination in Sera of Patients with Ovarian Tumors

Increasing evidence in the literature indicates that serum sialic acid is increased in cancer patients suggesting a possible usefulness of its determination as a tumor marker. However there are many discrepancies in the data reported, probably due to methodological errors, mainly in lipid bound sialic measurement. In this paper we illustrate the results obtained when we applied a method worked out in our laboratory for the determination of total and fractionated sialic acid (lipid and protein bound) to the analysis of sera from patients with ovarian tumors and the preliminary data on the follow up of selected cases. The potential pitfalls in using this relatively new tumor marker will be critically evaluated.

Download Full-text

The Determination of Urinary Oxypurines as Markers of Gastrointestinal Tumors

Tumori Journal ◽

10.1177/030089168707300313 ◽

1987 ◽

Vol 73 (3) ◽

pp. 289-294 ◽

Cited By ~ 5

Author(s):

Marco Lorenzi ◽

Daniela Vannoni ◽

Roberto Leoncini ◽

Ranieri Caldarone ◽

Enrico Marinello

Keyword(s):

High Pressure ◽

Liquid Chromatography ◽

Urinary Excretion ◽

Tumor Marker ◽

Cancer Patients ◽

Plasma Levels ◽

Colorectal Tumor ◽

Reverse Phase ◽

Tumor Bearing

Plasma levels and urinary excretion of oxypurines – hypoxanthine and xanthine – were evaluated by reverse-phase high-pressure liquid chromatography in 13 patients affected by gastric tumors and in 19 colorectal tumor-bearing patients. Preliminary results indicate higher values of urinary xanthine and an increase in the xanthine/hypoxanthine ratio in cancer patients. The increase was not generalized to all subjects, and did not appear related either to the stage of the disease or to CEA values. The limits within which the determination of urinary oxypurines can be employed as a tumor marker are discussed.

Download Full-text

Clinical Significance of the New Tumor Marker MCA in the follow-up of Patients with Mammary Carcinoma

The International Journal of Biological Markers ◽

10.1177/172460089300800210 ◽

1993 ◽

Vol 8 (2) ◽

pp. 130-132 ◽

Cited By ~ 1

Author(s):

J. Müller-Brand ◽

H. Mäcke

Keyword(s):

Breast Cancer ◽

Serum Concentration ◽

Tumor Marker ◽

Mammary Carcinoma ◽

Solid Phase ◽

Clinical Status ◽

Subsequent Increase ◽

Degree Of Differentiation

MCA is a mucin-like carcinoma-associated antigen which has been found in all breast cancer independent of histological type and degree of differentiation. A two-step solid-phase EIA was developed and the serum concentration of MCA was measured in 176 breast cancer patiens after surgery. Using a cutoff of 11.0 U/ml the test showed a sensitivity of 77% and a specifity of 82% when compared to clinical status. The predictive value of this tumor marker was 72% for a positive diagnosis and 93% for a negative diagnosis. Based on these observations it is recommended that determination of MCA values take place 2 to 3 times in the first postoperative week in all women with surgically treated mammary carcinoma. These MCA values should then serve as reference for further determinations, which should be performed at each check-up. A subsequent increase in the MCA value should be considered as a first sign of metastasis.

Download Full-text

The sensitivity and specifity of DR-70 as a tumor marker for gastrointestinal cancers.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.e22061 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. e22061-e22061

Author(s):

Burcak Erkol ◽

Basak Bala Oven ◽

Vedat Bayoglu ◽

Nurcan Paker ◽

Koray Kochan ◽

...

Keyword(s):

Tumor Marker ◽

Cancer Patients ◽

Sensitivity And Specificity ◽

Gastrointestinal Cancer ◽

Degradation Products ◽

Early Stage ◽

Gastrointestinal Cancers ◽

Predictive Values ◽

Significant Difference

e22061 Background: There is a great need to detect gastrointestinal cancers at an early stage, reduce morbidity and mortality. CEA and CA 19-9 are widely used serological markers for gastrointestinal cancers during follow-up. Their utility are limited because of their low sensitivity. In this study, a novel tumor marker DR-70 is evaluated for the sensitivity and specificity, relationship between clinical parameters and compared with CEA and CA 19-9. Methods: Blood sera of 101 histologically proven gastrointestinal cancer patients (38 female, 63 male; 42 colon, 25 rectum, 18 stomach, 9 pancreas, 4 esophagus and 3 cholangiocellular carcinomas) and 105 healthy blood donors were included. The TNM stage of the disease and histologic grade was shown. All patients and controls were also tested for CEA and CA 19-9 levels. In DR-70 immunoassay, the fibrin degradation products were quantitatively measured using ELISA DR-70 kits. Results: The median DR-70, CEA and CA19-9 levels were 1.6 µg/mL, 3.05 ng/mL and 22.2 IU/L in cancer patients, they were lower in healthy control 0.5 µg/mL, 0.9 ng/mL, 1.9 IU/L; p < 0.001. While the stage and grade increased, the levels of DR-70, CEA and CA-19-9 (p < 0.05) were increased significantly. DR-70 and CA19-9 values were highest in patients with pancreas, and lowest in rectum cancer, there was no statistically significant difference between tumor localization and CEA levels.The sensitivity, specificity and the cut-off value of DR-70, in patients with malignancy by using ROC analysis were found as 97%, 95% and < 0.75 µg/mL, respectively. The positive and negative predictive values were 95%, and 97% and the efficacy was 96%. Sensitivities of CEA (cut off value 3ng/mL) and CA 19-9 (cut off value 37 U/ml) were 52% and 39% respectively, the specificities were 94% and 99% for CEA and CA 19-9, respectively; sensitivity increased by combined use of both of them. Conclusions: Due to its high sensitivity and specificity, high positive and negative predictive values DR-70 can be used more frequently as a tumor marker for detection of gastrointestinal cancer. It can also be used in tumor progression and treatment follow-up because of positive correlation between DR-70 levels and the tumor stage.

Download Full-text

CANCER PATIENTS

The Professional Medical Journal ◽

10.29309/tpmj/2006.13.03.4979 ◽

2006 ◽

Vol 13 (03) ◽

pp. 344-348

Author(s):

MOHAMMAD JAWAID SABZWARI ◽

Muhammad Riaz ◽

MUKHTAR AHMAD ◽

Muhammad Umair ◽

MUHAMMAD TAHIR MAJEED

Keyword(s):

Sialic Acid ◽

Carcinoembryonic Antigen ◽

Cancer Patients ◽

Tumor Markers ◽

Age Distribution ◽

Laboratory Diagnosis ◽

Cancer Management ◽

Serum Sialic Acid ◽

Diagnosis Of Cancer ◽

Diagnostic Indicator

In the world cancer is one of the leading causes of death. Most cancerswhen detected early, can be potentially cured. Thus early laboratory diagnosis of cancer has great importance inmanagement. The tumor markers are one of the methods of cancer management in use today. Objectives: Tocompare serum sialic acid (SA) and carcinoembryonic antigen (CEA) as tumor markers in different cancer patients.Study Design: Prospective study Setting: Shaikh Zayed Medical Complex, Lahore. Material and Methods: Onehundred and fifty three (153) documented different cancer patients were studied to compare between serum sialic acidand carcinoembryonic antigen as a tumor marker along with fifty controls of matched sex and age distribution between30-85 years. The sialic acid was estimated by colorimetric procedure and carcinoembryonic antigen by EnzymeImmunoassay. Results: The results revealed that mean levels of sialic acid and CEA in cancer patients weresignificantly higher (p<0.05) as compared to controls, considering all malignancies together, or carcinoma,hematological malignancies and sarcoma alone. Statistical analysis showed sialic acid to be more sensitive (p<0.05)than CEA in detection of cancer. Conclusion: Sialic acid was seen to be a good diagnostic indicator as compared toCEA in most cancer patients.

Download Full-text

Serum Sialic Acid Levels in Lung Cancer Patients

Pharmacology ◽

10.1159/000136578 ◽

1976 ◽

Vol 14 (1) ◽

pp. 47-51 ◽

Cited By ~ 35

Author(s):

F.J. Krolikowski ◽

K. Reuter ◽

T.P. Waalkes ◽

S.M. Sieber ◽

R.H. Adamson

Keyword(s):

Lung Cancer ◽

Sialic Acid ◽

Cancer Patients ◽

Lung Cancer Patients ◽

Serum Sialic Acid

Download Full-text

Effect of Chemotherapy on Tumor Marker (Ca 15.3) and Serum in Breast Cancer Patients of Southern Eastern Region of Chhattisgarh; 6 Years Follow up Study

International Journal of Clinical Biochemistry and Research ◽

10.5958/2394-6377.2016.00004.6 ◽

2016 ◽

Vol 3 (1) ◽

pp. 16

Author(s):

Priyanka Chandel ◽

Harish Uraon ◽

Vivek Choudhary

Keyword(s):

Breast Cancer ◽

Tumor Marker ◽

Cancer Patients ◽

Eastern Region ◽

Breast Cancer Patients ◽

Ca 15.3 ◽

Follow Up Study

Download Full-text

Longitudinal follow-up of breast cancer patients with the tumor markers CA 549 and CA 15.3

The International Journal of Biological Markers ◽

10.1177/172460089501000106 ◽

1995 ◽

Vol 10 (1) ◽

pp. 30-34 ◽

Cited By ~ 2

Author(s):

L. Vankrieken ◽

F. Heureux ◽

J. Longueville ◽

R. De Hertogh

Keyword(s):

Breast Cancer ◽

Tumor Marker ◽

Cancer Patients ◽

Tumor Markers ◽

Clinical Situation ◽

Breast Cancer Patients ◽

Significant Information ◽

Ca 15.3 ◽

Cutoff Levels

In order to verify the efficiency of the tumor markers CA 15.3 and CA 549 in the follow-up of breast cancer patients, it was necessary first to check the cutoff levels of each tumor marker in women with an increased age-related risk, but with no evidence of disease. From 132 serum samples in this age group, we confirmed the CA 549 cutoff level of 12.1 U/ml. However, the cutoff of CA 15.3 was 34 U/ml, which is higher than previously reported in the literature. Fifty-two breast cancer patients with or without metastases at the time of entry into the study were followed for 2 to 3 years with both tumor markers. The sensitivity, specificity and the test efficiency for the presence of metastases were analyzed with each tumor marker. Taking into account the different cutoff levels, we concluded that both tumor markers can be used independently to follow the clinical situation of patients. In several cases an increase in both tumor markers was observed before a clinical diagnosis of metastases could be made. Combination of these two tumor markers gave no more significant information about the patient's clinical situation than each tumor marker alone.

Download Full-text